Subscribe
shutterstock_2179492463_jhvephoto
JHVEPhoto / Shutterstock.com
28 March 2023FeaturesAmericasMuireann Bolger

Amgen v Sanofi: Scotus grapples with enablement

The showdown between Amgen and Sanofi concerning the proper test for enablement under Section 112 of the US Patent Act has finally taken place at the US Supreme Court.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Sanofi wins enablement showdown at SCOTUS
18 May 2023   Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies.
Big Pharma
Amgen secures five-year ban on psoriasis drug copycat
20 April 2023   Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.
Big Pharma
Don’t distort enablement law, Amgen tells SCOTUS
9 March 2023   Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
Sanofi wins enablement showdown at SCOTUS
18 May 2023   Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies.
Big Pharma
Amgen secures five-year ban on psoriasis drug copycat
20 April 2023   Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.
Big Pharma
Don’t distort enablement law, Amgen tells SCOTUS
9 March 2023   Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand.

More on this story

Big Pharma
Sanofi wins enablement showdown at SCOTUS
18 May 2023   Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies.
Big Pharma
Amgen secures five-year ban on psoriasis drug copycat
20 April 2023   Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.
Big Pharma
Don’t distort enablement law, Amgen tells SCOTUS
9 March 2023   Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand.

More features

Sanofi unit loses genetic disorder patent at EPO after trio of challenges
INTA confirms London as host city for Annual Meeting 2026
INTA unveils key principles on AI and IP rights at Annual Meeting
Illumina takes aim at rival in gene sequencing spat
Novartis tops Big Pharma in global trademark portfolios
PierFerd hires partner with medtech expertise
NanoString to pay 10x Genomics $68m in global settlement
Federal Circuit revives CRISPR feud citing PTAB errors